ACTH: What Your Number Changes About Your Treatment

What ACTH Actually Measures

ACTH (adrenocorticotropic hormone) is a 39-amino-acid peptide released by the anterior pituitary gland. It travels through the bloodstream and signals the adrenal cortex to produce cortisol. The test captures a snapshot of pituitary-adrenal communication at the moment the blood is drawn.

Because ACTH follows a strong circadian pattern, peaking between 6:00 and 8:00 AM and dropping to its lowest point near midnight, the timing of the blood draw changes everything about interpretation. A value of 45 pg/mL at 8:00 AM is unremarkable. That same value at 11:00 PM is abnormal. Labs that process ACTH also require special handling: the sample must be collected in a pre-chilled EDTA tube, placed on ice immediately, and centrifuged within 30 minutes. Delays degrade the peptide and produce falsely low results [1].

ACTH never tells the full story alone. Clinicians pair it with a simultaneous serum cortisol draw, and often with a cosyntropin stimulation test, to distinguish between pituitary-driven and adrenal-driven disorders. The ratio between the two hormones is what changes the prescription pad.

The Normal Range and Why It Shifts

Most reference laboratories define a normal morning ACTH as 10 to 60 pg/mL (2.2 to 13.2 pmol/L). Some assays use a tighter window. The 2016 Endocrine Society Clinical Practice Guideline on adrenal insufficiency notes that "a morning plasma ACTH concentration above the upper limit of the reference range in combination with a low serum cortisol is diagnostic of primary adrenal insufficiency" [2].

Several factors shift ACTH independent of disease. Acute physical stress, surgery, and critical illness can push ACTH above 100 pg/mL transiently. Exogenous glucocorticoid use (even inhaled or topical) suppresses ACTH through negative feedback on the hypothalamic-pituitary axis. Pregnancy raises corticosteroid-binding globulin, which complicates cortisol interpretation without changing ACTH appreciably [3]. Chronic opioid therapy suppresses the entire HPA axis and can produce ACTH values below 5 pg/mL in up to 20% of long-term users.

One practical rule: if the patient used any glucocorticoid in the prior 6 weeks, ACTH and cortisol values cannot be interpreted at face value until a washout or stimulation test is performed.

High ACTH with Low Cortisol: Primary Adrenal Insufficiency

When ACTH is elevated (often above 100 pg/mL and sometimes exceeding 1,000 pg/mL) while morning cortisol sits below 3 mcg/dL, the adrenal glands themselves are failing. The pituitary is screaming for cortisol. Nobody is answering. This pattern defines primary adrenal insufficiency, historically called Addison disease.

The treatment pivot is immediate. Patients need both glucocorticoid and mineralocorticoid replacement because the adrenal cortex produces cortisol and aldosterone, and both are lost in primary disease. The Endocrine Society guideline recommends hydrocortisone 15 to 25 mg daily, split into two or three doses, with the largest dose given on waking to mimic normal circadian secretion [2]. Fludrocortisone at 0.05 to 0.2 mg daily replaces aldosterone. Without fludrocortisone, patients develop salt wasting, hypotension, and dangerous hyperkalemia.

ACTH levels also guide dose adequacy over time. An ACTH that remains markedly elevated (above 200 pg/mL) despite replacement may indicate underdosing. But the Endocrine Society warns against chasing a "normal" ACTH number: "We recommend against using serum ACTH to titrate glucocorticoid dose, as over-replacement to normalize ACTH increases metabolic risk" [2]. The target is symptom control, not a lab value.

A 2021 European registry study (EU-AIR, N=2,594) found that 34.2% of patients with primary adrenal insufficiency were receiving hydrocortisone doses above 25 mg per day, a figure associated with higher rates of obesity, diabetes, and osteoporosis compared to those dosed within guideline range [4].

Low ACTH with High Cortisol: Cushing Syndrome Workup

The opposite pattern, an ACTH below 5 pg/mL paired with elevated 24-hour urinary free cortisol or a failed 1 mg overnight dexamethasone suppression test, points to ACTH-independent Cushing syndrome. The cortisol excess is coming from an adrenal adenoma, carcinoma, or bilateral macronodular hyperplasia. The pituitary detects the surplus and shuts down its own ACTH output.

This result changes the diagnostic track entirely. Imaging shifts from pituitary MRI to adrenal CT. Treatment moves toward surgical resection rather than transsphenoidal surgery. The Endocrine Society's 2008 Cushing guideline (reaffirmed in subsequent reviews) states that "an undetectable or suppressed ACTH should prompt adrenal imaging as the next step" [5].

If ACTH instead measures between 20 and 100 pg/mL alongside biochemically confirmed hypercortisolism, ACTH-dependent Cushing becomes the working diagnosis. That points to either a pituitary adenoma (Cushing disease, roughly 70% of cases) or an ectopic ACTH-secreting tumor (small-cell lung cancer, bronchial carcinoid, or pancreatic neuroendocrine tumor). Inferior petrosal sinus sampling with CRH stimulation helps differentiate these two sources when pituitary MRI is equivocal [6].

Low ACTH with Low Cortisol: Secondary Adrenal Insufficiency

This is the most commonly encountered adrenal insufficiency pattern in clinical practice. Both ACTH and cortisol are low. The adrenal glands are capable of producing cortisol but receive no signal to do so. The failure sits upstream, in the pituitary or hypothalamus.

The most frequent cause is iatrogenic: prolonged exogenous glucocorticoid therapy (oral prednisone, injected triamcinolone, even potent topical betamethasone applied over large body surface areas) suppresses CRH and ACTH secretion through negative feedback. A study published in the Journal of Clinical Endocrinology & Metabolism found that 48% of patients receiving prednisone 7.5 mg or more daily for over 3 weeks had a subnormal response to cosyntropin stimulation [7]. Other causes include pituitary tumors, pituitary surgery, traumatic brain injury, and lymphocytic hypophysitis.

The treatment difference from primary AI is clinically significant. Patients with secondary adrenal insufficiency need glucocorticoid replacement only. They do not need fludrocortisone because the renin-angiotensin-aldosterone system remains intact when the adrenal zona glomerulosa is not destroyed [2]. Hydrocortisone dosing follows the same 15 to 25 mg range but may be lower (10 to 15 mg daily) in milder cases where some residual ACTH function remains.

These patients also require screening for other pituitary hormone deficiencies: TSH, LH, FSH, GH, and prolactin. A low ACTH from pituitary disease rarely comes alone.

How ACTH Levels Change Medication Decisions

The ACTH value does not just set the diagnosis. It shapes drug selection, dose titration, sick-day protocols, and long-term monitoring.

Drug selection. Primary AI (high ACTH) requires hydrocortisone plus fludrocortisone. Secondary AI (low ACTH) requires hydrocortisone alone. Some clinicians prefer prednisolone 3 to 5 mg daily or modified-release hydrocortisone (Plenadren, approved in the EU) for patients who struggle with multi-dose hydrocortisone schedules. In a 12-week crossover trial (N=64), Plenadren improved body weight and HbA1c compared to thrice-daily hydrocortisone [8].

Dose titration. Clinicians use symptoms (fatigue, nausea, postural hypotension, salt craving) rather than ACTH levels to adjust doses. Day-curve cortisol profiles, where serum cortisol is drawn before and 1 to 2 hours after each hydrocortisone dose, offer a more granular picture of replacement adequacy than a single ACTH draw.

Sick-day rules. Every patient on glucocorticoid replacement must carry an emergency injection kit (hydrocortisone sodium succinate 100 mg IM). During febrile illness, the standard guidance is to double or triple the oral hydrocortisone dose. This rule applies regardless of the ACTH level but becomes life-critical in primary AI, where adrenal crisis mortality runs between 5% and 10% per event even with treatment [9].

Monitoring. The Endocrine Society recommends clinical assessment every 3 to 6 months after stabilization. Annual checks should include body weight, blood pressure, electrolytes (especially sodium and potassium), fasting glucose, and bone density screening if glucocorticoid doses exceed 20 mg hydrocortisone equivalent daily [2].

ACTH Stimulation Testing: The Confirmatory Step

A single morning ACTH and cortisol pair raises suspicion. The 250 mcg cosyntropin (Cortrosyn) stimulation test confirms it. Synthetic ACTH is injected intravenously, and cortisol is measured at 0, 30, and 60 minutes. A peak cortisol below 18 mcg/dL (some labs use 16 mcg/dL with newer immunoassays) confirms adrenal insufficiency.

The test has well-documented limitations. The 250 mcg dose is supraphysiologic, delivering roughly 100 times more ACTH than a normal pituitary pulse. In early or partial secondary AI, the adrenal glands may still respond to this flood of synthetic ACTH despite being understimulated day to day. For this reason, some endocrinologists prefer the 1 mcg (low-dose) cosyntropin test, which more closely mimics physiologic ACTH exposure and may detect milder deficiency earlier [10]. A meta-analysis of 12 studies found that the low-dose test had a sensitivity of 80% versus 63% for the standard-dose test in detecting secondary AI, though specificity was comparable (85% vs. 87%) [10].

The insulin tolerance test (ITT) remains the gold standard for hypothalamic-pituitary-adrenal axis integrity, particularly when evaluating GH deficiency simultaneously. Hypoglycemia (glucose below 40 mg/dL) provokes a stress cortisol response. A peak cortisol above 18 mcg/dL rules out central AI. The ITT is contraindicated in patients with seizure disorders or coronary artery disease [11].

ACTH in the Context of Hormone Replacement Therapy

For patients on testosterone replacement therapy (TRT) or estrogen-based HRT, ACTH testing carries specific clinical nuances. Testosterone does not directly alter ACTH secretion, but it influences cortisol-binding globulin (CBG) concentrations. Testosterone therapy lowers CBG, which can reduce total cortisol measurements without changing free (bioactive) cortisol [12]. Clinicians aware of this artifact avoid misdiagnosing adrenal insufficiency in men on TRT based solely on a low total cortisol.

Estrogen therapy has the opposite effect. Oral estrogen raises CBG substantially, increasing total cortisol by 50% or more while free cortisol remains stable. This is well documented in the Endocrine Society's 2017 hormone therapy guidelines and means that standard cortisol cutoffs on stimulation testing may need upward adjustment in women on oral (but not transdermal) estrogen [13].

For patients taking GLP-1 receptor agonists such as semaglutide or tirzepatide, no clinically meaningful interaction with the HPA axis has been identified in the STEP or SURMOUNT trial programs [14]. Weight loss itself, however, can reduce cortisol clearance rates. A 10% body weight reduction may lower cortisol metabolite excretion by approximately 15 to 20%, which could theoretically affect dose requirements in patients already on hydrocortisone replacement.

When to Retest and When to Refer

Retesting ACTH makes sense in defined clinical scenarios. After pituitary surgery, ACTH recovery may take 6 to 18 months, and serial testing every 3 months helps determine whether glucocorticoid replacement can be tapered. After discontinuation of chronic exogenous steroids, an annual cosyntropin stimulation test guides safe withdrawal. In patients with known pituitary adenomas managed conservatively, semiannual ACTH and cortisol draws screen for progressive hypopituitarism.

Referral to endocrinology is appropriate when the ACTH-cortisol pattern is discordant with the clinical picture, when ACTH exceeds 300 pg/mL despite replacement, when ectopic ACTH secretion is suspected, or when the patient presents with features of Cushing syndrome. Any patient who experiences an adrenal crisis should be referred for subspecialty management and sick-day education. The European Journal of Endocrinology published a 2020 consensus recommending that all newly diagnosed adrenal insufficiency patients receive structured education on emergency glucocorticoid injection within 30 days of diagnosis [15].

Patients with ACTH levels persistently above the reference range while on replacement therapy should have their medication timing, adherence, and absorption assessed before any dose increase. Switching from hydrocortisone to modified-release formulations or adjusting dose timing to 30 minutes before waking (using an alarm-based protocol) can reduce morning ACTH spikes without increasing total daily glucocorticoid exposure.